Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients

Internal Medicine

Volumn 51, Issue 16, 2012, Pages 2097-2104

  Yamada, Shunsuke ^a   Yoshida, Hisako ^a   Taniguchi, Masatomo ^a   Tanaka, Shigeru ^a   Eriguchi, Masahiro ^a   Nakano, Toshiaki ^a   Tsuruya, Kazuhiko ^a   Kitazono, Takanari ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Hyperphosphatemia; Lanthanum carbonate; Nutrition; Peritoneal dialysis; Phosphate binder

Indexed keywords

ALBUMIN; CALCIUM; CALCIUM CARBONATE; CINACALCET; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PROTON PUMP INHIBITOR; SEVELAMER;

ABDOMINAL PAIN; ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONSTIPATION; CREATININE CLEARANCE; DIALYSATE LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; INDIGESTION; LOW DRUG DOSE; MALE; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; RETROSPECTIVE STUDY; SHORT STATURE;

ADULT; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PARATHYROID HORMONE; PERITONEAL DIALYSIS; PHOSPHATES; RETROSPECTIVE STUDIES;

EID: 84865129419     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6814     Document Type: Article

References (24)

1. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458-482, 1990.
2. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequence and treatment in patients with chronic renal disease. Am J Kidney Dis 19: 303-317, 1999.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004.
4. Nordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT. Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The Kidney Disease Outcome and Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 23: 925-932, 2005.
5. Noordzij M, Korevaar JC, Bos WJ, et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 21: 2513-2520, 2006.
6. Wang AY, Woo J, Sea MM, Lau MC, Lui SF, Li PK. Hyperphos-phatemia in Chinese peritoneal dialysis patients with or without residual kidney function; what are the implications? Am J Kidney Dis 43: 712-720, 2004.
7. Gokal R. The preferred phosphate binder in dialysis patients. Perit Dial Int 19: 405-408, 1999.
8. Hutchinson AJ. Oral phosphate binders. Kidney Int 75: 906-914, 2009.
9. Drueke T. Lanthanum carbonate as a first-line phosphate binder: the cons. Semin Dial 20: 329-332, 2007.
10. Shigematsu T, and the Lanthanum Carbonate Group. Multicenter prospective randomized double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol 70: 404-410, 2008.
11. Al-Baaj FA, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant 20: 775-782, 2005.
12. Kawanishi H, Ishida M, Ishizaki M, et al. Lanthanum carbonate treatment of patients with hyperphosphatemia undergoing CAPD. Perit Dial Int 28: 673-675, 2008.
13. Kazama JJ. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism. Ther Apher Dial 11 (Suppl 1): S44-S47, 2007.
14. Malluche HH, Siami GA, Swanepoel C, et al. Improvement in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70: 284-295, 2008.
15. Ben-Dov IZ, Pappo O, Sklair-Levy M, et al. Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol Dial Transplant 22: 362-368, 2007.
16. Neven E, Dams G, Postnov A, et al. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Nephrol Dial Transplant 24: 1790-1799, 2009
17. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 16 (Suppl 2): S107-S114, 2005.
18. Arenas MD, Malek T, Alvarez-Ude F, Cil MT, Moledous A, Reig-Ferrer A. Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control. Nefrologia 30: 522-530, 2010.
19. Curran MP, Robinson DM. Lanthanum carbonate. A review of its use in lowering serum phosphate in patients with end-stage renal disease. Drugs 69: 2329-2349, 2009.
20. Daugirdas JT, Finn WF, Emmett M, et al. The phosphate binder equivalent dose. Semin Dial 24: 41-49, 2011.
21. Hutchison AJ, Laville M.; SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 23: 3677-3684, 2008.
22. Ho LC, Wang HH, Chiang CK, Hung KY, Wu KD. Malnutritioninflammation score independently determined cardiovascular and infection risk in peritoneal dialysis patients. Blood Purif 30: 16-24, 2010.
23. Chung SH, Lindholm B, Lee HB. Influence of nutritional status on continuous ambulatory peritoneal dialysis patient survival. Perit Dial Int 20: 19-26, 2000.
24. Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 74: 148-157, 2008.